Filing Flows › Ideaya Biosciences (IDYA) › Guidance & outlook
Ideaya Biosciences (IDYA) guidance and outlook
Ideaya Biosciences' 10-Q filed Nov 3, 2026 makes 22 forward-looking statements.
Guidance and outlook
Forward-looking statements, 10-Q filed Nov 3, 2026
- Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease.
- We are conducting a global Phase 1/2 trial of IDE849 in extensive-stage SCLC (ES-SCLC) and NEC and plan to provide our first clinical data from this trial by the end of 2026 or early in 2027.
- FDA, we plan to initiate two Phase 3 registrational trials with IDE849 in ES-SCLC and NEC by the end of 2026.
- We are conducting a Phase 1 dose escalation trial and are targeting to provide a clinical data update in 2027.
- We will sponsor and conduct the clinical trial and Roche will provide clinical supply of RG6505, with a goal of initiating a Phase 1 combination trial by the end of the year.
- Genentech will sponsor and conduct the trial and we will provide clinical supply of IDE892.
- We have incurred significant operating losses to date and expect that our operating expenses will increase significantly as we advance our product candidates through preclinical and clinical development; seek regulatory approval and prepare for, and, if approved, proceed to commercialization; acquire, discover, validate and develop additional product candidates; obtain, maintain, protect and enforce our…
- Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through the sale of equity, debt financings or other capital sources, including potential collaborations with other companies or other strategic transactions.
- To date, we have not generated any revenue from product sales, and we do not expect to generate any revenue from product sales unless and until we are able to obtain regulatory approval and commercialize one of our product candidates in the future.
- We will also recognize revenue from regulatory milestones as they are achieved.
- If the actual timing of the performance of services or the level of effort varies from the original estimates, we will adjust the accrual accordingly.
- Nonrefundable payments made prior to the receipt of goods or services that will be used or rendered for future research and development activities are deferred and capitalized as prepaid expenses and other current assets on our balance sheet.
Ideaya Biosciences' latest quarter
Ideaya Biosciences, Q3 2026: revenue $10.2M (-95% year over year), net loss $126M, operating cash flow −$93.5M. The chart follows the revenue to costs, profit and cash.
Questions
What does Ideaya Biosciences expect?
Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We are conducting a global Phase 1/2 trial of IDE849 in extensive-stage SCLC (ES-SCLC) and NEC and plan to provide our first clinical data from this trial by the end of 2026 or early in 2027. FDA, we plan to initiate two Phase 3 registrational trials with IDE849 in ES-SCLC and NEC by the end of
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.